All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
Ensuring “Safety” Remains the Hallmark of Homeopathic OTCs
By Mark Land, M.S., RAC-US, AAHP President Monitoring and reporting on the safety of homeopathic drug products is a multifaceted undertaking that begins in the...
Potential Nitrosamine Impurities in Your Products?
By Robert Sven Jechlitschka, Director of Quality and Development, Schwabe Pharma México In September 2024, the Food and Drug Administration published a final guidance document...
Lowest Permissible Attenuation
By Eric L. Foxman, HPCUS Senior Scientist While many might be familiar with the nomenclature and concept of "First Safe Dilution" (FSD), the Homeopathic Pharmacopeia...
The FDA Adverse Event Reporting System (FAERS)
By Kristina Skowronek, Dir. of Quality and Regulatory Compliance, Boiron, Inc. The FDA Adverse Event Reporting System (FAERS) has a public dashboard online where healthcare...
Update — Lawsuit Challenges FDA’s Homeopathic Regulatory Policy
By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA's characterization of homeopathic products as unapproved new drugs will not be decided...
AAHP 2025 Outlook
By Mark Land, M.S., RAC-US, AAHP President To support the growth of member companies' businesses and address issues in our new environment, the AAHP Board...
A Year of Change
By Mark Land, M.S., RAC-US, AAHP President This year 2025 is poised to be one of the most dynamic years in recent memory. Everyone is...
